Optimization and evaluation of Lisinopril mucoadhesive sustained release matrix pellets: In-vitro and ex-vivo studies

Alagili, Modhi F; AlQuadeib, Bushra T.; Ashri, Lubna Y.; Abbas, Ibrahim S.

doi:10.1016/j.jsps.2023.06.023

Cited by 4 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 2 × 2 × 2 cm wooden cubicle block tied with intestinal membrane was dipped in Krebb's buffer solution till the upper layer of mucosa was. The tablet was adhered to the glass slide with cyanoacrylate glue and allowed to maintain contact with the membrane under a constant weight of 5 g. Mucoadhesive strength was determined for both T1F1 and T2F3 with n = 3 by estimating the force necessary to break the contact between the tablet surface and intestinal mucosa [25,26].…”

Section: Mucoadhesive Strengthmentioning

confidence: 99%

IVIVC assessment, pharmacokinetic evaluation, and X-ray radiography mapping of Novel Parteck® SRP 80 and hypromellose-loaded LTD4 receptor antagonist chronosystem

Jawed,

Satish

2023

Futur J Pharm Sci

View full text Add to dashboard Cite

Background The current research aims to determine the pharmacokinetic parameters, mucoadhesive strength, and IVIVC correlation of the novel chronotherapeutic drug delivery system of montelukast sodium (MTS) loaded Parteck® SRP80 and hypromellose system. To accomplish this, an HPLC method was developed which is highly sensitive, precise, and rapid for quantifying pure MTS in rabbit plasma. Mucoadhesive strength and time-dependent mobility of developed formulation were established by ex-vivo study and X-ray radiography, respectively. Using a fraction of drug absorbed (FDA) and a fraction of drug released (FDR), Level-A in-vitro in-vivo correlation (IVIVC) was developed. According to ICH Q1A (R2) standards, stability experiments were conducted for 180 days. Result MTS retention time came as 3.971 min with a mobile phase of methanol: acetonitrile: 0.2 mM sodium acetate buffer (5:90:5). In-vitro dissolution showed pulsatile release of the drug up to 24 h with two lag phases. The in-vivo study showed a Cmax of 490.16 ± 33.95 ng/ml, Tmax of 9 h, and MRT of 14.08 ± 1.21 h. The correlation coefficient of 0.9899 confirmed the level-A IVIVC. Uncoated matrix tablet of Parteck® SRP 80 displayed mucoadhesive strength 1.25-fold higher than hypromellose. Stability experiments found no significant changes in drug content, physical appearance, and cumulative percentage release with a similarity factor of 87–90. Conclusion A single oral dose in-vivo study proved the sustained release of the drug for 24 h with satisfactory mucoadhesive strength. Moreover, X-ray radiography has confirmed the time-dependent presence of formulation at the needed spot. This study fulfilled all the requirements for chronotherapy of asthma and can be scaled up in the future. Graphical abstract

show abstract

Section: Mucoadhesive Strengthmentioning

confidence: 99%

IVIVC assessment, pharmacokinetic evaluation, and X-ray radiography mapping of Novel Parteck® SRP 80 and hypromellose-loaded LTD4 receptor antagonist chronosystem

Jawed,

Satish

2023

Futur J Pharm Sci

View full text Add to dashboard Cite

show abstract

Modulation of intestinal permeability of 5-fluorouracil via phospholipid interaction based lipophilic complex designing and pharmacokinetic assessment

Kumar,

Singh Arya,

Jindal

2024

Journal of Dispersion Science and Technology

View full text Add to dashboard Cite

Gastroretentive Drug Delivery Systems

Kulkarni,

Sherkar,

Kudhekar

et al. 2024

Novel Drug Delivery Systems (Part 1)

View full text Add to dashboard Cite

Administration through the oral route is the most accessible and preferred due to its many advantages. Most of the drugs administered orally show poor bioavailability due to less residing time at the gastric absorption site. To boost the bioavailability of such drugs, it is important to extend the residing time of the drug in the upper GIT, which can be achieved by using gastroretentive drug delivery systems (GRDDS). There are multiple conventional and advanced gastroretentive systems based on various mechanisms, namely high-density systems, floating systems, magnetic systems, mucoadhesive systems, expandable systems, raft-forming systems, and many more. Novel techniques like 3D printing technology are also an emerging approach in the fabrication of GRDDS. Various in vitro and in vivo techniques are used for the analysis of GRDDS, like buoyancy time, gastroscopy, scintigraphy, ultrasonography, etc. This chapter is the comprehensive literature exploring GRDDS, including various principles in the fabrication of GRDDS, techniques of preparation of GRDDS, polymers used in the fabrication of GRDDS, evaluation of GRDDS, application of 3D printing in GRDDS, and patent scenario.

show abstract

Optimization and evaluation of Lisinopril mucoadhesive sustained release matrix pellets: In-vitro and ex-vivo studies

Cited by 4 publications

References 36 publications

IVIVC assessment, pharmacokinetic evaluation, and X-ray radiography mapping of Novel Parteck® SRP 80 and hypromellose-loaded LTD4 receptor antagonist chronosystem

IVIVC assessment, pharmacokinetic evaluation, and X-ray radiography mapping of Novel Parteck® SRP 80 and hypromellose-loaded LTD4 receptor antagonist chronosystem

Modulation of intestinal permeability of 5-fluorouracil via phospholipid interaction based lipophilic complex designing and pharmacokinetic assessment

Gastroretentive Drug Delivery Systems

Contact Info

Product

Resources

About